These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34600258)

  • 21. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 22. Improving methadone access for rural communities in the USA: lessons learned from COVID-19 adaptations and international models of care.
    Lister JJ; Lister HH
    Rural Remote Health; 2021 Nov; 21(4):6770. PubMed ID: 34757760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The new services that opioid treatment programs have adopted in response to COVID-19.
    Cantor J; Laurito A
    J Subst Abuse Treat; 2021 Nov; 130():108393. PubMed ID: 34118694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia.
    Haggerty T; Khodaverdi M; Dekeseredy P; Wood N; Hendricks B; Peklinsky J; Sedney CL
    J Subst Abuse Treat; 2022 May; 136():108687. PubMed ID: 34903397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
    Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioid treatment programs, telemedicine and COVID-19: A scoping review.
    Chan B; Bougatsos C; Priest KC; McCarty D; Grusing S; Chou R
    Subst Abus; 2022; 43(1):539-546. PubMed ID: 34520702
    [No Abstract]   [Full Text] [Related]  

  • 28. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
    Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
    J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Sign Me Up": a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic.
    Darnton JB; Bhatraju EP; Beima-Sofie K; Michaels A; Hallgren KA; Soth S; Grekin P; Woolworth S; Tsui JI
    Addict Sci Clin Pract; 2023 Mar; 18(1):21. PubMed ID: 36991506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year.
    Bart G; Wastvedt S; Hodges JS; Rosenthal R
    J Subst Abuse Treat; 2022 Feb; 133():108590. PubMed ID: 34373169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
    Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
    J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore.
    Abidogun TM; Cole TO; Massey E; Kleinman M; Greenblatt AD; Seitz-Brown CJ; Magidson JF; Belcher AM
    J Subst Use Addict Treat; 2023 Feb; 145():208946. PubMed ID: 36880915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years.
    Bortz C; Armistead I; Bonaguidi A; Coyle DT
    J Subst Use Addict Treat; 2024 Jun; 161():209342. PubMed ID: 38513975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the COVID-19 Pandemic on Functions of Nursing Professionals in the Care of Opioid Use Disorder: Systematic Review.
    Brown KG; Chen CY; Dong D; Lake KJ; Butelman ER
    J Addict Nurs; 2024 Apr-Jun 01; 35(2):107-113. PubMed ID: 38830000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment provider perceptions of take-home methadone regulation before and during COVID-19.
    Madden EF; Christian BT; Lagisetty PA; Ray BR; Sulzer SH
    Drug Alcohol Depend; 2021 Nov; 228():109100. PubMed ID: 34600251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
    Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM; Schnell MK; Schwandt H; Zhang J
    JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States.
    Lambdin BH; Bluthenthal RN; Tookes HE; Wenger L; Morris T; LaKosky P; Kral AH
    Drug Alcohol Depend; 2022 Aug; 237():109504. PubMed ID: 35688052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.